Literature DB >> 26508157

Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.

Cristina d'Abramo1, Christopher M Acker2, Joel B Schachter3, Giuseppe Terracina4, Xiaohai Wang3, Stefanie K Forest2, Peter Davies5.   

Abstract

In the attempt to elucidate if the "peripheral sink hypothesis" could be a potential mechanism of action for tau removal in passive immunotherapy experiments, we have examined tau levels in serum of chronically injected JNPL3 and Tg4510 transgenic animals. Measurement of tau in serum of mice treated with tau antibodies is challenging because of the antibody interference in sandwich enzyme-linked immunosorbent assays. To address this issue, we have developed a heat-treatment protocol at acidic pH to remove interfering molecules from serum, with excellent recovery of tau. The present data show that pan-tau and conformational antibodies do increase tau in mouse sera. However, these concentrations in serum do not consistently correlate with reductions of tau pathology in brain, suggesting that large elevations of tau species measured in serum are not predictive of efficacy. Here, we describe a reliable method to detect tau in serum of transgenic animals that have undergone tau immunotherapy. Levels of tau in human serum are less than the sensitivity of current assays, although artifactual signals are common. The method may be useful in similarly treated humans, a situation in which false positive signals are likely.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular tau; Human antibodies against mouse immunoglobulin; Tau ELISA; Tau immunotherapy; Tau in serum

Mesh:

Substances:

Year:  2015        PMID: 26508157      PMCID: PMC4688074          DOI: 10.1016/j.neurobiolaging.2015.09.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

1.  The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients.

Authors:  M V Pimm; A C Perkins; N C Armitage; R W Baldwin
Journal:  J Nucl Med       Date:  1985-09       Impact factor: 10.057

2.  Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

Authors:  Marc I Diamond; David M Holtzman; Kiran Yanamandra; Najla Kfoury; Hong Jiang; Thomas E Mahan; Shengmei Ma; Susan E Maloney; David F Wozniak
Journal:  Neuron       Date:  2013-09-26       Impact factor: 17.173

3.  The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments.

Authors:  Sadasivam Jeganathan; Martin von Bergen; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  Biochemistry       Date:  2008-09-11       Impact factor: 3.162

4.  Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

Authors:  Ludovic Collin; Bernd Bohrmann; Ulrich Göpfert; Krisztina Oroszlan-Szovik; Laurence Ozmen; Fiona Grüninger
Journal:  Brain       Date:  2014-07-31       Impact factor: 13.501

5.  "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy.

Authors:  F J Primus; E A Kelley; H J Hansen; D M Goldenberg
Journal:  Clin Chem       Date:  1988-02       Impact factor: 8.327

6.  Study of an enzyme immunoassay kit for carcinoembryonic antigen.

Authors:  R Maiolini; A Bagrel; C Chavance; B Krebs; B Herbeth; R Masseyeff
Journal:  Clin Chem       Date:  1980-11       Impact factor: 8.327

7.  Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects--incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme.

Authors:  R J Thompson; A P Jackson; N Langlois
Journal:  Clin Chem       Date:  1986-03       Impact factor: 8.327

8.  Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons.

Authors:  Jessica W Wu; Mathieu Herman; Li Liu; Sabrina Simoes; Christopher M Acker; Helen Figueroa; Joshua I Steinberg; Martin Margittai; Rakez Kayed; Chiara Zurzolo; Gilbert Di Paolo; Karen E Duff
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

9.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

10.  Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.

Authors:  Clara Theunis; Natalia Crespo-Biel; Valérie Gafner; Maria Pihlgren; María Pilar López-Deber; Pedro Reis; David T Hickman; Oskar Adolfsson; Nathalie Chuard; Dorin Mlaki Ndao; Peter Borghgraef; Herman Devijver; Fred Van Leuven; Andrea Pfeifer; Andreas Muhs
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more
  7 in total

1.  Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.

Authors:  Kiran Yanamandra; Tirth K Patel; Hong Jiang; Suzanne Schindler; Jason D Ulrich; Adam L Boxer; Bruce L Miller; Diana R Kerwin; Gilbert Gallardo; Floy Stewart; Mary Beth Finn; Nigel J Cairns; Philip B Verghese; Ilana Fogelman; Tim West; Joel Braunstein; Grace Robinson; Jennifer Keyser; Joseph Roh; Stephanie S Knapik; Yan Hu; David M Holtzman
Journal:  Sci Transl Med       Date:  2017-04-19       Impact factor: 17.956

2.  Oligomeric tau-targeted immunotherapy in Tg4510 mice.

Authors:  Sulana Schroeder; Aurelie Joly-Amado; Ahlam Soliman; Urmi Sengupta; Rakiz Kayed; Marcia N Gordon; David Morgan
Journal:  Alzheimers Res Ther       Date:  2017-06-27       Impact factor: 6.982

3.  Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.

Authors:  Francesca Vitale; Luca Giliberto; Santiago Ruiz; Kristen Steslow; Philippe Marambaud; Cristina d'Abramo
Journal:  Acta Neuropathol Commun       Date:  2018-08-22       Impact factor: 7.801

4.  In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice.

Authors:  Eliot J Davidowitz; Pavan K Krishnamurthy; Patricia Lopez; Heidy Jimenez; Leslie Adrien; Peter Davies; James G Moe
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Development and validation of a high-sensitivity assay for measuring p217+tau in plasma.

Authors:  Gallen Triana-Baltzer; Setareh Moughadam; Randy Slemmon; Kristof Van Kolen; Clara Theunis; Marc Mercken; Hartmuth C Kolb
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-27

6.  Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.

Authors:  Hamad Yadikar; Isabel Torres; Gabrielle Aiello; Milin Kurup; Zhihui Yang; Fan Lin; Firas Kobeissy; Richard Yost; Kevin K Wang
Journal:  PLoS One       Date:  2020-07-21       Impact factor: 3.240

7.  Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models.

Authors:  Francesca Vitale; Jasmin Ortolan; Bruce T Volpe; Philippe Marambaud; Luca Giliberto; Cristina d'Abramo
Journal:  Acta Neuropathol Commun       Date:  2020-08-06       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.